Considerations for SGLT2 inhibitor use in post-transplantation diabetes

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been recommended for the treatment of patients with type 2 diabetes mellitus and cardiovascular disease, heart failure or chronic kidney disease. Findings from recent efficacy and safety trials of empagliflozin in kidney transplant recipients with post-transplantation diabetes are timely, given the elevated cardiovascular risk associated with solid organ transplantation.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Jenssen, T. & Hartmann, A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat. Rev. Endocrinol. 15, 172–188 (2019).

  2. 2.

    DeFronzo, R. A., Norton, L. & Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11–26 (2017).

  3. 3.

    Schwaiger, E. et al. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am. J. Transplant. 19, 907–919 (2019).

  4. 4.

    Halden, T. A. S. et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 42, 1067–1074 (2019).

  5. 5.

    Handelsman, Y. et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of Sglt-2 inhibitors and diabetic ketoacidosis. Endocr. Pract. 22, 753–762 (2016).

  6. 6.

    Davies, M. J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61, 2461–2498 (2018).

Download references

Acknowledgements

The Empa-Renal Tx study from Oslo, Norway, was initiated and funded by the investigators and supported by grants from the South-Eastern Norway Regional Health Authority, the Norwegian Diabetes Association and Oslo Diabetes Research Centre. This study was supported by an unrestricted grant from Boehringer Ingelheim, Norway.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Manfred Hecking or Trond Jenssen.

Ethics declarations

Competing interests

T.J. has received lecture honoraria from Boehringer Ingelheim, AstraZeneca and Merck Sharp & Dohme. M.H. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hecking, M., Jenssen, T. Considerations for SGLT2 inhibitor use in post-transplantation diabetes. Nat Rev Nephrol 15, 525–526 (2019). https://doi.org/10.1038/s41581-019-0173-0

Download citation

Further reading